



US009408910B2

(12) **United States Patent**
Ryu et al.

(10) **Patent No.:** **US 9,408,910 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **ANTICANCER PRODRUG ACTIVATED BY RADIATION OR ULTRAVIOLET TREATMENT AND USE THEREOF**

(75) Inventors: **Ju-Hee Ryu**, Seoul (KR); **Kwang-Meyung Kim**, Seoul (KR); **Ick-Chan Kwon**, Seoul (KR); **Kui-Won Choi**, Seoul (KR); **Sang-Yoon Kim**, Seoul (KR); **Beom-Suk Lee**, Seoul (KR); **Dae-Yoon Chi**, Seoul (KR); **Hee-Seup Kil**, Seoul (KR); **Hyun-Ju Sung**, Seoul (KR)

(73) Assignee: **KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY**, Seoul (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/001,745**

(22) PCT Filed: **Mar. 2, 2011**

(86) PCT No.: **PCT/KR2011/001438**

§ 371 (c)(1),
(2), (4) Date: **Aug. 27, 2013**

(87) PCT Pub. No.: **WO2012/118237**

PCT Pub. Date: **Sep. 7, 2012**

(65) **Prior Publication Data**

US 2013/0338422 A1 Dec. 19, 2013

(51) **Int. Cl.**

A61K 41/00 (2006.01)
A61N 5/06 (2006.01)
A61N 5/10 (2006.01)
A61K 47/48 (2006.01)
A61K 31/704 (2006.01)
A61K 38/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 41/0042** (2013.01); **A61K 31/704** (2013.01); **A61K 47/48246** (2013.01); **A61N 5/062** (2013.01); **A61N 5/1001** (2013.01); **A61K 38/00** (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2004/0052793 A1* 3/2004 Carter A61K 47/48246
424/146.1
2007/0104719 A1 5/2007 Carter et al.
2008/0193431 A1* 8/2008 Zheng A61K 47/48053
424/94.1

OTHER PUBLICATIONS

Kyu-Chul, Kim, "Development of a prodrug activated by caspase-3," www.riss.kr/link?id=T11929818, uploaded Feb 2010, Abstract.*
Law, Benedict et al. "Proteolysis: A Biological Process Adapted in Drug Delivery, Therapy, and Imaging." *Bioconjugate Chemistry* vol. 20, No. 9, Sep. 2009, pp. 1683-1695.
Stefflova, Klara et al. "Targeted Photodynamic Therapy Agent with a Built-In Apoptosis Sensor for in Vivo Near-Infrared Imaging of Tumor Apoptosis Triggered by Its Photosensitization in Situ." *Molecular imaging* vol. 5, No. 4, 2006, pp. 520-532.
Rai, Prakash, et al. "Development and applications of photo-triggered theranostic agents." *Advanced Drug Delivery Reviews* vol. 62, 2010, pp. 1094-1124.
Wojtyk, James TC, et al. "Exploiting tumour biology to develop novel drug delivery strategies for PDT." *Medical Laser Application*, vol. 21, 2006, pp. 225-238.
Kim, Sungwon, et al. "Engineered polymers for advanced drug delivery." *European Journal of Pharmaceutics and Biopharmaceutics* vol. 71, 2009, pp. 420-430.
Tamm, Ingo, et al. "IAP-Family Protein Survivin Inhibits Caspase Activity and Apoptosis Induced by Fas (CD95), Bax, Caspases, and Anticancer Drugs." *Cancer Research*, vol. 58, 1998, pp. 5315-5320. International Search Report mailed Dec. 21, 2011 in corresponding International Application No. PCT/KR2011/001438.
Kyu-Chul Kim, "Development of a prodrug activated by capase-3," www.riss.kr/link?id=T11929818, uploaded Feb. 2010, Abstract.

* cited by examiner

Primary Examiner — Amber D Steele

Assistant Examiner — Schuyler Milton

(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(57) **ABSTRACT**

The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.

7 Claims, 27 Drawing Sheets
(20 of 27 Drawing Sheet(s) Filed in Color)